ReviewCancers2021
Recent Advances in Zinc Oxide Nanoparticles (ZnO NPs) for Cancer Diagnosis, Target Drug Delivery, and Treatment.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 1 synthesis or guideline pooled it.
- ZnO-Based Nanoparticles for Targeted Cancer Chemotherapy and the Role of Tumor Microenvironment: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Sustainable nanomedicine from olive leaf waste: biosynthesized ZnONPs with mechanistic validation against hepatocellular carcinoma.RSC advances · 2026Article
- Effect of Zinc Oxide Nanoparticles From Infant Formula Milk Powder on Colon Cells In Vitro.Journal of applied toxicology : JAT · 2026Article
- Silymarin and Zinc Oxide Nanoparticles Attenuate Experimental Colon Cancer in Rats Through Crosstalk of miR-192 and β-Catenin Pathways.Biomolecules · 2026Article
- Anticancer Activity of Green Synthesized ZnO Nanoparticles fromNanomaterials (Basel, Switzerland) · 2026Article
- Comparative In Vitro Response of HaCaT and A375 Melanoma Cells to Zinc Oxide Nanoparticles Synthesized Using Puerarin.Journal of xenobiotics · 2026Article
- Fluorescent-Conjugated ZnO Nanostructures Exhibited 3D Anti-Tumor Efficacy Against Drug-Resistant Cancers Through Cholesterol-Mediated ROS Regulation.Antioxidants (Basel, Switzerland) · 2026Article
- ZnO@PDA@Ag nanocomposite-mediated delivery of 9-bromonoscapine, an anticancer agent, for enhanced lung cancer therapy.Nanoscale advances · 2026Article
- Combined effects of Lenvatinib and zinc oxide nanoparticles by promoting apoptosis and anti-proliferative activity in mice bearing Ehrlich solid tumors.Discover nano · 2026Article
- Green-SynthesizedBiomimetics (Basel, Switzerland) · 2026Article
- A novel therapeutic strategy against gastric carcinoma: artemisia sieberi-derived biogenic zno nanoparticles inducing intrinsic apoptosis and suppressing AGS cell proliferation.Scientific reports · 2026Article
- Evaluating the mechanisms and therapeutic potential of ZnO nanoparticles as selective anticancer agents for lung malignancies.Discover nano · 2026Review
- Synergistic effects of Ag and Cu doping in ZnO: improved photoluminescence, antibacterial, and catalytic performance.Scientific reports · 2026Article
- Nanotechnology in Cancer Therapy: How Nanoparticles Are Shaping the Future of Personalized Treatment.ACS nano medicine · 2026Review
- Reusable biogenic fabrication and structural analysis of Phyllanthus acidus-derived ZnO nanoparticles: Photocatalytic degradation of methylene blue dye and its biological applications.Scientific reports · 2026Article
- Probiotic-derived EPS-ZnO nanoparticles: therapeutic potential in colorectal cancer gene regulation.Cancer cell international · 2026Article
- The therapeutic potential of zinc-nanoparticles against the cerebellar neurotoxicity induced by bacterial lipopolysaccharides in female rats and their pups.Scientific reports · 2026Article
- Peganum harmala leaf extract mediated green synthesised polyvinyl alcohol zinc oxide beta cyclodextrin nanocomposite for anticancer and antimicrobial applications.Discover nano · 2026Article
- Poly(lactic-co-glycolic acid) immunomodulatory nanoparticles attenuate neuroinflammation and Alzheimer's disease-related pathology in 5xFAD mice.bioRxiv : the preprint server for biology · 2026Article
- Biomedical utility of zinc and copper mediated cerium oxide nanoparticles.RSC advances · 2026Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cancer is regarded as one of the most deadly and mirthless diseases and it develops due to the uncontrolled proliferation of cells. To date, varieties of traditional medications and chemotherapies have been utilized to fight tumors. However, their immense drawbacks, such as reduced bioavailability, insufficient supply, and significant adverse effects, make their use limited. Nanotechnology has evolved rapidly in recent years and offers a wide spectrum of applications in the healthcare sectors. Nanoscale materials offer strong potential for curing cancer as they pose low risk and fewer complications. Several metal oxide NPs are being developed to diagnose or treat malignancies, but zinc oxide nanoparticles (ZnO NPs) have remarkably demonstrated their potential in the diagnosis and treatment of various types of cancers due to their biocompatibility, biodegradability, and unique physico-chemical attributes. ZnO NPs showed cancer cell specific toxicity via generation of reactive oxygen species and destruction of mitochondrial membrane potential, which leads to the activation of caspase cascades followed by apoptosis of cancerous cells. ZnO NPs have also been used as an effective carrier for targeted and sustained delivery of various plant bioactive and chemotherapeutic anticancerous drugs into tumor cells. In this review, at first we have discussed the role of ZnO NPs in diagnosis and bio-imaging of cancer cells. Secondly, we have extensively reviewed the capability of ZnO NPs as carriers of anticancerous drugs for targeted drug delivery into tumor cells, with a special focus on surface functionalization, drug-loading mechanism, and stimuli-responsive controlled release of drugs. Finally, we have critically discussed the anticancerous activity of ZnO NPs on different types of cancers along with their mode of actions. Furthermore, this review also highlights the limitations and future prospects of ZnO NPs in cancer theranostic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.